Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BTP7

UPID:
FAP24_HUMAN

ALTERNATIVE NAMES:
Fanconi anemia-associated protein of 24 kDa

ALTERNATIVE UPACC:
Q9BTP7; B3KY46; Q8WUJ7; Q96FX6

BACKGROUND:
The Fanconi anemia core complex-associated protein 24, with its alternative name Fanconi anemia-associated protein of 24 kDa, is integral to the DNA repair process. It specifically targets the FANCM/FAAP24 complex to DNA, with a preference for single-strand DNA, thereby playing a key role in the recruitment of the FA core complex to damaged DNA sites and influencing FANCD2 monoubiquitination upon DNA damage.

THERAPEUTIC SIGNIFICANCE:
The exploration of Fanconi anemia core complex-associated protein 24's function offers promising avenues for therapeutic intervention. Given its critical role in DNA repair and chromosomal stability, targeting this protein could lead to innovative treatments for diseases where DNA repair is compromised, offering hope for advancements in genetic disorder therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.